A Comprehensive Approach to Managing People With Diabetes and Chronic Kidney Disease

Abstract

Get full access to this article

View all access options for this article.

References

Neumiller

Alicic

Tuttle

KR.

Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease. Clin Kidney J. 2023;17(1):sfad285. doi:10.1093/ckj/sfad285

Deshpande

Harris-Hayes

Schootman

Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254-1264.

Tonelli

Muntner

Lloyd

, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807-814.

de Boer

Khunti

Sandusky

, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-309.

American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standard of care in diabetes- 2024. Diabetes Care. 2024;47(suppl 1):S219-S230.

Komenda

Ferguson

Macdonald

, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789-797.

Miller

Kaufman

Levey

, et al. National Kidney Foundation Laboratory Engagement Working Group recommendations for implementing the CKD-EPI 2021 race-free equations for estimated glomerular filtration rate: practical guidance for clinical laboratories. Clin Chem. 2022;68(4):511-520.

Delgado

Baweja

Crews

, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79(2):268-288.e1.

Christofedes

Desai

Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes mellitus: addressing the barriers to albuminuria testing. J Prim Care Community Health. 2021;12:21501327211003683. doi:10.1177/21501327211003683

10.

Stevens

Levey

AS.

Current status and future perspectives for CKD testing. Am J Kidney Dis. 2009;53(3, suppl3):S17-S26.

11.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-S314.

12.

Rowe

Sitch

Barratt

, et al. Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease. Kidney Int. 2019;96(2):429-435.

13.

Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1-S127.

14.

American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024. Diabetes Care. 2024;47(suppl 1):S145-S157.

15.

The EMPA-KIDNEY Collaborative Group, Herrington

Staplin

, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127.

16.

Heerspink

HJL

Stefansson

Correa-Rotter

, et al. Dapa-gliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446.

17.

Perkovic

Jardine

Neal

, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306.

18.

Currie

Taylor

Fujita

, et al. Effect of mineralocor-ticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17(1):127. doi:10.1186/s12882-016-0337-0

19.

Bakris

Agarwal

Anker

, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229.

20.

Pitt

Filippatos

Agarwal

, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252-2263.

21.

Marso

Bain

Consoli

, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.

22.

Marso

Daniels

Brown-Frandsen

, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.

23.

Sattar

Lee

MMY

Kristensen

, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662.

24.

Perkovic

Tuttle

Rossing

, et al. Effects of sema-glutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347.